Healthcare
Mdxhealth Announces Peer-Reviewed Publication of Oxford GPS-ProMPT Study in European Urology Oncology, Establishing Scientific Foundation for the Landmark GPS-ProtecT Randomized Controlled Trial
Mdxhealth Announces Peer-Reviewed Publication of Oxford GPS-ProMPT Study in European Urology Oncology, Establishing Scientific Foundation for the Landmark GPS-ProtecT Randomized Controlled Trial IRVINE, California – June 29, 2026– Mdxhealth SA (NASDAQ: MDXH) (the "Company" or "mdxhealth"), a leader in urology-focused precision diagnostics, today announced the peer-reviewed publication of the Oxford GPS-ProMPT study in European Urology Oncology, one of the world’s leading journals in genitourinar
About this update from Mdxhealth Sa
Mdxhealth Announces Peer-Reviewed Publication of Oxford GPS-ProMPT Study in European Urology Oncology, Establishing Scientific Foundation for the Landmark GPS-ProtecT Randomized Controlled Trial IRVINE, California – June 29, 2026– Mdxhealth SA (NASDAQ: MDXH) (the "Company" or "mdxhealth"), a leader in urology-focused precision diagnostics, today announced the peer-reviewed publication of the Oxford GPS-ProMPT study in European Urology Oncology, one of the world's leading journals in genitourinary oncology. The publication represents the first major peer-reviewed milestone from the Oxford collaboration and serves as the foundation for evidence to be produced by the landmark GPS-ProtecT study. "The acceptance of Professor Freddie Hamdy's GPS-ProMPT study in European Urology Oncology is an important milestone in our collaboration with the University of Oxford. These findings provide the scientific foundation for the ongoing GPS-ProtecT study, which has the potential to establish GPS mdx as the first genomic classifier supported by randomized clinical trial evidence in localized prostate cancer," said Michael K. McGarrity, Chief Executive Officer of mdxhealth. "This publication supports our advancement of GPS with regard to guideline development, payer coverage, and physician adoption." Lead author Dr Nikita Sushentsev, Cambridge University Hospitals NHS Foundation of Trust, commented, "The ProMPT findings demonstrate that patients with favorable GPS mdx scores achieved excellent long-term outcomes — including 92% freedom-from-failure at six years in active surveillance and up to 100% in surgery and radiotherapy cohorts — even among those with adverse clinical risk factors. This suggests GPS mdx can identify favorable tumor biology that traditional risk stratification alone would miss, with meaningful implications for how we counsel patients facing treatment decisions." About the GPS-ProMPT StudyThe GPS-ProMPT study, titled, "Genomic Prostate Score for identifying biologically low-risk disease in patients with prostate cancer undergoing active surveillance, surgery, or radiotherapy," evaluated 409 men over a period of more than six years with localized or locally advanced prostate cancer managed with Active Surveillance, Radical Prostatectomy, or Radiotherapy and demonstrated that GPS mdx predicts long-term oncologic outcomes across multiple treatment pathway...